Cas no 612501-52-7 (4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol)
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol Chemical and Physical Properties
Names and Identifiers
-
- 4-(3-chloro-2-fluoroanilino)-6-hydroxy-7-methoxyquinazoline
- 4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol
- 4-(3-Chloro-2-fluoroanilino)-6-hydroxy-7- methoxyquinazoline
- 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-ol
- VZBZUFGPXJGXNJ-UHFFFAOYSA-N
- AK549879
- 4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-ol
- 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-hydroxyquinazoline
- 4-[(3-chloro-2-fluor
- 612501-52-7
- DS-19512
- SY270757
- 4-[(3-chloro-2-fluoro-phenyl)amino]-6-hydroxy-7-methoxy-quinazoline
- C75866
- 4-[(3-chloro-2-fluorophenyl)amino]-6-hydroxy-7-methoxyquinazoline
- SCHEMBL202827
- AKOS030528100
- MFCD26394834
- DB-304984
- CS-0163225
- 4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol
-
- MDL： MFCD26394834
- Inchi： 1S/C15H11ClFN3O2/c1-22-13-6-11-8(5-12(13)21)15(19-7-18-11)20-10-4-2-3-9(16)14(10)17/h2-7,21H,1H3,(H,18,19,20)
- InChI Key： VZBZUFGPXJGXNJ-UHFFFAOYSA-N
- SMILES： ClC1=CC=CC(=C1F)NC1=C2C=C(C(=CC2=NC=N1)OC)O
Computed Properties
- Exact Mass: 319.0523825g/mol
- Monoisotopic Mass: 319.0523825g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 6
- Heavy Atom Count: 22
- Rotatable Bond Count: 3
- Complexity: 379
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 67.3
- XLogP3: 3.8
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol Security Information
- Signal Word：Warning
- Hazard Statement： H302-H315-H319-H335
- Warning Statement： P261-P305+P351+P338
- Storage Condition：Keep in dark place,Inert atmosphere,Room temperature
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Alichem | A019123252-5g |
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol |
612501-52-7 | 97% | 5g |
$189.00 | 2023-09-01 | |
| Alichem | A019123252-10g |
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol |
612501-52-7 | 97% | 10g |
$295.80 | 2023-09-01 | |
| Alichem | A019123252-25g |
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol |
612501-52-7 | 97% | 25g |
$585.80 | 2023-09-01 | |
| TRC | C989233-50mg |
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol |
612501-52-7 | 50mg |
$ 50.00 | 2022-06-06 | ||
| TRC | C989233-100mg |
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol |
612501-52-7 | 100mg |
$ 65.00 | 2022-06-06 | ||
| TRC | C989233-500mg |
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol |
612501-52-7 | 500mg |
$ 115.00 | 2022-06-06 | ||
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-KP658-50mg |
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol |
612501-52-7 | 97% | 50mg |
85CNY | 2021-05-08 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-KP658-250mg |
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol |
612501-52-7 | 97% | 250mg |
246CNY | 2021-05-08 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-KP658-5g |
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol |
612501-52-7 | 97% | 5g |
604.0CNY | 2021-07-10 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-KP658-1g |
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol |
612501-52-7 | 97% | 1g |
143.0CNY | 2021-07-10 |
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol Related Literature
-
Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151
-
Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
-
Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
-
J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
Additional information on 4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol
Recent Advances in the Study of 4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol (CAS: 612501-52-7)
4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol (CAS: 612501-52-7) is a quinazoline derivative that has garnered significant attention in recent years due to its potential therapeutic applications, particularly in oncology. This compound belongs to a class of small-molecule inhibitors that target key signaling pathways involved in cancer progression. Recent studies have focused on elucidating its mechanism of action, pharmacokinetic properties, and efficacy in preclinical models.
One of the most notable findings in recent research is the compound's ability to selectively inhibit epidermal growth factor receptor (EGFR) tyrosine kinase activity. EGFR is a well-established target in cancer therapy, and mutations or overexpression of this receptor are associated with various malignancies. In vitro studies have demonstrated that 4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol exhibits potent inhibitory effects on EGFR phosphorylation, leading to downstream suppression of cell proliferation and induction of apoptosis in cancer cell lines.
Further investigations have explored the compound's pharmacokinetic profile, revealing favorable oral bioavailability and metabolic stability. Animal studies have shown that the compound achieves sufficient plasma concentrations to exert its antitumor effects, with minimal off-target toxicity. These findings suggest that 4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol could be a promising candidate for further development as an oral anticancer agent.
In addition to its direct effects on EGFR, recent research has uncovered the compound's potential to modulate other signaling pathways, including PI3K/AKT and MAPK/ERK. These pathways are frequently dysregulated in cancer and contribute to tumor growth, survival, and resistance to therapy. The multi-targeted activity of 4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol may enhance its therapeutic efficacy and reduce the likelihood of resistance development.
Despite these promising results, challenges remain in optimizing the compound's selectivity and minimizing potential side effects. Ongoing research is focused on structural modifications to improve its pharmacological properties and expand its therapeutic window. Collaborative efforts between academic institutions and pharmaceutical companies are underway to advance this compound through preclinical and clinical development.
In conclusion, 4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol represents a promising avenue for cancer therapy, with its unique mechanism of action and favorable pharmacokinetic profile. Continued research and development efforts are essential to fully realize its potential and translate these findings into clinical applications.
612501-52-7 (4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol) Related Products
- 650577-95-0(7-Quinazolinol, 4-[(3,4-dichloro-2-fluorophenyl)amino]-6-methoxy-, hydrochloride (1:))
- 848440-16-4(6,7-Quinazolinediol, 4-[(3-chloro-2-fluorophenyl)amino]-, 6-acetate)
- 193001-59-1(7-Quinazolinol, 4-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-)
- 153437-03-7(4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6,7-dimethoxy-,monohydrochloride)
- 655248-21-8(4-Quinazolinamine, N-(3-chloro-2,4-difluorophenyl)-6,7-dimethoxy-)
- 184475-71-6(FAAH-IN-2)
- 848440-15-3(4-(3-chloro-2-fluoroanilino)-6,7-dihydroxyquinazoline)
- 196603-66-4(Ethanol,2-[[4-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]-)
- 196603-47-1(ZM 306416 Hydrochloride)
- 690206-97-4(ZM 306416)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
